The ranking in this dataset covers 100 companies, and it is heavily front-loaded: the leading assignee holds 197 of the 2,164 records in scope, and the top five together hold 863 records, or 39.9% of the field. Past the top ten, which together hold 61.3% of records, filing counts drop off quickly into a long tail of organisations with only a handful of records each. That shape matters for licensing strategy — a handful of names control most of the mechanical claim space around barrel, plunger and needle-shield design.

Filing volume has plateaued rather than grown or collapsed. The last three complete filing years show 189 filings in 2021 against 188 in 2024, a -1% change, after an earlier peak of 218 filings in 2019. Figures for 2025 and 2026 look lower still, but that reflects the roughly 18-month lag between filing and publication rather than a real drop in activity, so they should not be read as a downturn.

The underlying search combines core hardware terms with specific failure modes: silicone oil migration, break loose force, tungsten residue, glass delamination, needle shield interaction and container closure integrity. Device claims (A61M) touch 69.1% of the 2,164 records, more than double the 27.4% share for medicinal-preparation claims (A61K), which means most of the contested ground is the mechanical interface between barrel, stopper and needle rather than the drug formulation itself.